Velo3D says Mears orders sixth Sapphire XC 3D printer
Bitget2026/10/06 13:02Mears Machine ordered a sixth Sapphire XC metal 3D printer from Velo3D, expanding its production fleet. System will be dedicated to copper-nickel printing, targeting shipyard and offshore demand for corrosion-resistant components. Move adds a new alloy family to Mears’ in-house additive capacity, alongside existing nickel superalloy and aluminum production. Order supports a U.S.-based copper-nickel production supply chain, positioning Mears to offer tooling-free replacements for legacy cast parts. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Velo3D Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060900PR_NEWS_USPR_____LA64739) on October 06, 2026, and is solely responsible for the information contained therein.
- Mears Machine ordered a sixth Sapphire XC metal 3D printer from Velo3D, expanding its production fleet.
- System will be dedicated to copper-nickel printing, targeting shipyard and offshore demand for corrosion-resistant components.
- Move adds a new alloy family to Mears’ in-house additive capacity, alongside existing nickel superalloy and aluminum production.
- Order supports a U.S.-based copper-nickel production supply chain, positioning Mears to offer tooling-free replacements for legacy cast parts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.